VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2011

Jul 18, 2011

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2011-07-15

Reporting Person: MUELLER PETER (EVP, Global R&D, CSO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2011-07-15	Common Stock	M	2500	$10.41	Acquired	136235	Direct
2011-07-15	Common Stock	S	2500	$50.68	Disposed	133735	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2011-07-15	Stock Options	$10.41	M	2500	Disposed	2015-02-02	Common Stock (2500)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	4495	Indirect

Footnotes

F1: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1.

F2: Open market sales reported on this line occurred at a weighted average price of $50.68 (range $50.29 to $51.12).

F3: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4: Fully vested.